BFRI News and Press, Biofrontera Inc. From 04/08/22

Gainers: MedAvail (MDVL) +72%. Lyra Therapeutics (LYRA) +31%. TSR (TSRI) +24%. Biofrontera (BFRI) +18%. Takung Art (TKAT) +16%. Akanda (AKAN) +15%. Mullen Automotive (MULN) +16%. Nurix Therapeutics (NRIX) +14%. Borr Drilling (BORR) +14%. EPAM Systems (EPAM) +13%. Losers: Kaleid...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re diving into the top penny stocks for today in our market update for Friday! Source: John Brueske/Shutterstock.com Before we get to the meat of this article, I’ve got to warn you about the potential...

The shares of Biofrontera (NASDAQ:BFRI) are trading higher for the second straight session on Friday to reach the highest level since January after the dermatology-focused biopharma company said its growth momentum returned in 2021. Chief Executive of Biofrontera (BFRI) Erica Monaco made the ...

Gainers: MedAvail MDVL +61%. Lyra Therapeutics LYRA +27%. Medicenna Therapeutics (MDNA) +25%. Biofrontera BFRI +23%. IsoPlexis (ISO) +8%. Losers: BioCryst Pharmaceuticals BCRX -33%. Sunshine Biopharma SBFM -33%. Werewolf Therapeutics (HOWL) -15%. I...

Buying Penny Stocks Today? What You Need to Know About Trading Penny Stocks With the end of another week of trading penny stocks and blue chips, there is a lot for investors to consider. While this week has been extremely volatile, today we are beginning to see signs of a bullish turnar...

Biofrontera (NASDAQ:BFRI) rose pre-market April 8 after it said that 2022 revenue is expected to increase by at least 30% compared to 2021. Q4 total revenue grew +6.95% Y/Y to $9.17M. Full year 2021 revenue rose by +27.86% to $24.1M. “Despite continued challenges resulting from the COV...

Biofrontera press release (NASDAQ:BFRI): Q4 GAAP EPS of -$1.29. Revenue of $9.17M (+7.0% Y/Y) Total revenues are expected to increase by at least 30% compared with 2021, including first quarter total revenues up by over 100% versus the first quarter prior year and typical seasonal strength in...

I ntroduces 2022 financial guidance Conference call begins at 11 :0 0 a .m. Eastern time today WOBURN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”) , a biopharmaceutical ...

WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today preliminary, unaudited product revenues for the quarter ended March 31, 2022. Pr...

WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31,...